Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
Korobelnik JF, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, Fitzpatrick S, Leal S, Brunck L, Hasanbasic Z, Chu KW, Reed K, Sivaprasad S. Korobelnik JF, et al. Among authors: lanzetta p. Eye (Lond). 2024 Dec;38(17):3218-3221. doi: 10.1038/s41433-024-03312-w. Epub 2024 Aug 31. Eye (Lond). 2024. PMID: 39217260 Free PMC article. No abstract available.
The role of OCT-A in retinal disease management.
Rodríguez FJ, Staurenghi G, Gale R; Vision Academy Steering Committee. Rodríguez FJ, et al. Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2019-2026. doi: 10.1007/s00417-018-4109-3. Epub 2018 Sep 3. Graefes Arch Clin Exp Ophthalmol. 2018. PMID: 30175386 Free PMC article. Review.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.
Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Teo KYC, et al. Among authors: lanzetta p. Eye (Lond). 2024 Oct 8. doi: 10.1038/s41433-024-03370-0. Online ahead of print. Eye (Lond). 2024. PMID: 39379523 Review.
Prevalence and causes of vision loss in East Asia: 1990-2010.
Wong TY, Zheng Y, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Price H, White RA, Resnikoff S, Taylor HR, Bourne RR; Vision Loss Expert Group of the Global Burden of Disease Study. Wong TY, et al. Br J Ophthalmol. 2014 May;98(5):599-604. doi: 10.1136/bjophthalmol-2013-304047. Epub 2014 Jan 3. Br J Ophthalmol. 2014. PMID: 24390167 Review.
A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.
Rosenblatt A, Udaondo P, Cunha-Vaz J, Sivaprasad S, Bandello F, Lanzetta P, Kodjikian L, Goldstein M, Habot-Wilner Z, Loewenstein A; ARTES Study Group. Rosenblatt A, et al. Among authors: lanzetta p. Ophthalmology. 2020 Mar;127(3):377-393. doi: 10.1016/j.ophtha.2019.10.005. Epub 2019 Oct 10. Ophthalmology. 2020. PMID: 31932090 Free article.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
Prevalence and causes of vision loss in Central and South Asia: 1990-2010.
Jonas JB, George R, Asokan R, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Price H, Vijaya L, White RA, Wong TY, Resnikoff S, Taylor HR, Bourne RR; Vision Loss Expert Group of the Global Burden of Disease Study. Jonas JB, et al. Br J Ophthalmol. 2014 May;98(5):592-8. doi: 10.1136/bjophthalmol-2013-303998. Epub 2014 Jan 23. Br J Ophthalmol. 2014. PMID: 24457361 Review.
Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections.
Cheng CY, Wang N, Wong TY, Congdon N, He M, Wang YX, Braithwaite T, Casson RJ, Cicinelli MV, Das A, Flaxman SR, Jonas JB, Keeffe JE, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Resnikoff S, Silvester AJ, Tahhan N, Taylor HR, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study. Cheng CY, et al. Br J Ophthalmol. 2020 May;104(5):616-622. doi: 10.1136/bjophthalmol-2018-313308. Epub 2019 Aug 28. Br J Ophthalmol. 2020. PMID: 31462416
247 results